In Vitro Susceptibilities of Bloodstream Isolates of Rare Candida Species against Ravuconazole and Three Licensed antifungal Agents.

M.A. PFALLER, D.J. DIEKEMA, S.A. MESSER, L. BOYKEN, R.J. HOLLIS, R. JONES

Author address: 

Univ. of Iowa Coll. of Med., Iowa City, IA, Jones Microbiology Institute, North Liberty, IA.

Abstract: 

Background: Over 90% of Candida bloodstream infections are due to only four species (C. albicans, C. glabrata, C. parapsilosis and C. tropicalis). While the in vitro susceptibility of these species to new and investigational antifungal agents is well documented, the same data is not available for the less commonly isolated species. Methods: A total of 332 unique bloodstream isolates (duplicate isolates excluded) of Candida were tested, including 134 C. krusei, 81 C. guilliermondii, 65 C. lusitaniae, 15 C. famata, 13 C. kefyr, 6 C. pelliculosa, 4 C. rugosa, 3 C. dubliniensis, 3 C. inconspicua, 3 C. lipolytica, 2 C. sake, and 1 isolate each of C. lambica, C. norvegensis, and C. zeylanoides. We determined the minimum inhibitory concentrations (MICs) of all antifungal agents by broth microdilution performed according to National Committee for Clinical Laboratory Standards (NCCLS) method using RPMI 1640. NCCLS breakpoints were used for fluconazole and flucytosine, and provisional breakpoints of £ 1 µg/ml for ravuconazole and amphotericin B were used for comparison purposes. Results: Ravuconazole demonstrated excellent activity overall (MIC90, 0.5 µg/ml, 97% inhibited at MIC £ 1 µg/ml). Only 9 isolates had ravuconazole MICs of > 1 µg/ml (3 C. krusei, 4 C. guilliermondii, 1 C. inconspicua and 1 C. sake). By contrast, fluconazole, flucytosine and amphotericin B demonstrated decreased activities (
2003

abstract No: 

M-1223

Full conference title: 

43rd Interscience Conference on Antimicrobial Agents
    • ICAAC 43rd